A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Clinical trial NCT07776691 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07776691
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-22
- Primary completion
- 2032-03-19
- Enrollment
- 802
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.